In a major development, the Drug Controller of India has given permission to Bharat Biotech, manufacturer of indigenously made Covaxin, for using its intranasal vaccine iNCOVACC, for emergency use in India.

According to a media statement from M/s Bharat Biotech, "iNCOVACC has received approval under Restricted Use in Emergency Situations for ages 18 and above. Phase III trials were conducted for safety and immunogenicity in 3,100 subjects, in 14 trial sites across India. Heterologous booster dose studies were conducted for safety and immunogenicity in 875 subjects, with BBV154 intranasal vaccine administered post 2 doses of the two commonly administered Covid-19 vaccines. The trials were conducted in 9 trial sites across India.